Nonalcoholic Steatohepatitis
HERALD: Thyroid receptor agonist well-tolerated, lowers liver fat in MASH at 12 weeks
SAN DIEGO — Once-daily ALG-055009 achieved “significant and robust reductions” in liver fat at 12 weeks and was well-tolerated among noncirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to data.
Denifanstat a ‘promising oral therapy’ for the treatment of MASH, related fibrosis
Patients treated with denifanstat 50 mg vs. placebo achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis, according to study results in The Lancet Gastroenterology & Hepatology.
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
This activity is supported by an educational grant from Novo Nordisk.
Health care professionals ‘thrilled’ with approval of first treatment for MASH
An analysis of the global online conversations of more than 1,600 healthcare professionals has revealed celebration at news of the approval of the first treatment for adults with metabolic dysfunction-associated steatohepatitis.
Top in endocrinology: Incretin-based therapies; updated diabetes guidance
Incretin-based therapies, which were developed for the treatment of diabetes and obesity because of their ability to target defects that are not addressed by other medications, are continuing to evolve.
Novel therapies targeting bile acid-triggered pathways may benefit children with NASH
Medications that target bile acid-triggered pathways and combination therapies could be the key for treating nonalcoholic steatohepatitis for young people with obesity and type 2 diabetes, according to a speaker.
ENLIVEN extension topline data: Pegozafermin sustains ‘robust benefits’ in NASH at week 48
Topline findings from an extension of the phase 2b ENLIVEN trial showed that pegozafermin sustained improvements in fibrosis and disease resolution for patients with nonalcoholic steatohepatitis at 48 weeks, 89bio announced.
Up to 67% of patients achieve MASH resolution at 36 weeks with efruxifermin
BOSTON — Treatment with efruxifermin resulted in “clinically meaningful” but not yet statistically significant benefit at 36 weeks in cirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to late-breaking data.
VIDEO: TERN-501 ‘could be a best-in-class molecule’ alone, as combination therapy for MASH
BOSTON — Treatment with TERN-501, a selective thyroid hormone receptor beta agonist, reduced liver fat content and fibro-inflammation among patients with presumed metabolic dysfunction-associated steatohepatitis, late-breaking data showed.
‘Significant differences’ reported by race, ethnicity in transplant rates for MASH-HCC
BOSTON — Hispanic and Asian patients with metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma were less likely to undergo liver transplantation compared with other races and ethnicities, data showed.